GlassScriptPhysician profile
Manish S Bhandari
NPI 1356337430
$1,437.02
in general payments reported to CMS, 2019-2025
29 companies · $49.00 in 2025
The $49.00 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $221 · 2021: $87.35 · 2022: $94.31 · 2024: $42.97 · 2025: $49.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.00 · Education: $42.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.00 |
| Education | $42.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $190.04 | 2019-2021 | |
| Pfizer INC. | $135.34 | 2019 | |
| Janssen Biotech, INC. | $129.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $110.21 | 2019-2024 | Enhertu |
| Abbvie INC. | $108.40 | 2019-2025 | |
| Eisai INC. | $103.07 | 2019-2022 | |
| Astellas Pharma US INC | $85.24 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $83.43 | 2019-2020 | |
| Incyte Corporation | $61.31 | 2022 | |
| Merck Sharp & Dohme LLC | $52.60 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $49.73 | 2021 | |
| Lilly USA, LLC | $48.92 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $43.44 | 2019 | |
| Foundation Medicine, INC. | $38.88 | 2019 | |
| Genentech USA, INC. | $23.83 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $20.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.43 | 2019 | |
| Puma Biotechnology, INC. | $18.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Emd Serono, INC. | $15.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.51 | 2019 | |
| Dendreon Pharmaceuticals LLC | $12.19 | 2020 | |
| Clovis Oncology, INC. | $12.00 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $11.82 | 2019 | |
| Exelixis INC. | $11.60 | 2019 | |
| Epizyme, INC. | $11.50 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.